Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SHSE:600750's PEG Ratio is ranked better than 62.57% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.775
vs SHSE:600750: 1.19
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
China Resources Jiangzhong Pharmaceutical Co PEG Ratio Related Terms
China Resources Jiangzhong Pharmaceutical Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Jiangzhong Pharmaceutical Co PEG Ratio Chart
China Resources Jiangzhong Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Jiangzhong Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Jiangzhong Pharmaceutical Co PEG Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) has a PEG Ratio of 1.19 as of Jul. 22, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. This is 30% below median its historical median of 1.70. Over the past decade, China Resources Jiangzhong Pharmaceutical Co's PEG Ratio has ranged from 0.94 to 3.72. According to the industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #131 out of 350 companies in the Drug Manufacturers industry, placing it in the top 37.4%.
Is China Resources Jiangzhong Pharmaceutical Co's PEG Ratio too high?
China Resources Jiangzhong Pharmaceutical Co's current PEG Ratio of 1.19 is 30% below median its 10-year median of 1.70. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 3.72. The Drug Manufacturers industry median PEG Ratio is 1.78. China Resources Jiangzhong Pharmaceutical Co's value of 1.19 is 33% below this industry median. Based on the distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #131 out of 350 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Jiangzhong Pharmaceutical Co has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Jiangzhong Pharmaceutical Co's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #131 out of 350 companies for PEG Ratio. This puts China Resources Jiangzhong Pharmaceutical Co in the upper half of its industry. The industry median PEG Ratio is 1.78. China Resources Jiangzhong Pharmaceutical Co's value of 1.19 is 33% below this benchmark. Historically, China Resources Jiangzhong Pharmaceutical Co's own PEG Ratio has ranged from 0.94 to 3.72 over the past decade. While the company's 10-year median is 1.70 vs. the industry median of 1.78, China Resources Jiangzhong Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.78, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Jiangzhong Pharmaceutical Co's current PEG Ratio of 1.19 is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Jiangzhong Pharmaceutical Co's current PEG Ratio is 1.19, which is 30% below median its own 10-year median of 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Jiangzhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥21.34, compared to a current price of ¥25.20 — trading 18.1% above its estimated fair value. The current PEG Ratio is 1.19, which is 30% below median its 10-year median of 1.70 and 33% below the Drug Manufacturers industry median of 1.78. China Resources Jiangzhong Pharmaceutical Co's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For China Resources Jiangzhong Pharmaceutical Co (SHSE:600750), the current PEG Ratio is 1.19 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥25.20 is trading 18.1% above its estimated GF Value™ of ¥21.34.
GuruFocus considers China Resources Jiangzhong Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600750:
PEG Ratio: 1.19 (30% below median its 10-year median of 1.70)
GF Value™: ¥21.34 vs. price of ¥25.20 (18.1% above fair value)
Industry Position: 33% below the Drug Manufacturers median (#131 of 350)
No single metric tells the full story. See the SHSE:600750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Jiangzhong Pharmaceutical Co Business Description
China Resources Jiangzhong Pharmaceutical Co Ltd is engaged in the research and development, production, and sale of over-the-counter pharmaceuticals and health-related products, including functional foods. Its business activities also include the production and sale of proprietary Chinese medicines and chemical drugs.
92GF Score
Get the complete analysis for SHSE:600750
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600750 has been successfully added to your 
